Latest News

AAD updates guidelines for managing AD with phototherapy and systemic therapies


 

FROM JAMA DERMATOLOGY

Using the guidelines in clinical care

According to Dr. Davis, the topic of which agent if any should be considered “first line” generated robust discussion among the work group members.

“When there are not robust head-to-head trials – and there are not – it is often opinion that governs this decision, and opinion should not, when possible, govern a guideline,” Dr. Davis said. “Accordingly, we determined based upon the evidence agents – plural – that deserve to be considered ‘first line’ but not a single agent.”

In her opinion, the top three considerations regarding use of systemic therapy for AD relate to patient selection and shared decision making. One, standard therapy has failed. Two, diagnosis is assured. And three, “steroid phobia should be considered,” and patients should be “fully informed of risks and benefits of both treating and not treating,” she said.

Dr. Sidbury reported that he serves as an advisory board member for Pfizer, a principal investigator for Regeneron, an investigator for Brickell Biotech and Galderma USA, and a consultant for Galderma Global and Micreos. Dr. Davis reported having no relevant disclosures. Other work group members reported having financial disclosures with many pharmaceutical companies. The study was supported by internal funds from the American Academy of Dermatology.

Pages

Recommended Reading

Can this tool forecast peanut allergies?
Federal Practitioner
Facial, hand, and foot dermatitis: Lebrikizumab and dupilumab show efficacy in new studies
Federal Practitioner
Expunging ‘penicillin allergy’: Your questions answered
Federal Practitioner
AD in infancy: Diagnostic advice and treatment tips
Federal Practitioner
Can online mindfulness and self-compassion training improve quality of life for patients with atopic dermatitis?
Federal Practitioner
JAK-inhibitor safety in adolescents with AD: Long-term analyses reported
Federal Practitioner
Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitis
Federal Practitioner
Dupilumab outcomes stable at end of open label atopic dermatitis study
Federal Practitioner
Abrocitinib remains effective at 96 weeks, in older as well as younger adults
Federal Practitioner
Advising patients on AD treatment options: Expert pearls
Federal Practitioner